在肥胖的发展和治疗中的内分泌大麻素系统:寻找新的想法
Anna Serefko1, Joanna Lachowicz-Radulska1, Monika Elżbieta Jach2
1Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.
International journal of molecular sciences
|October 16, 2025
概括
内分泌大麻素系统 (ECS) 与肥胖有关. 调节ECS对抗肥胖的效果有希望,但临床翻译面临安全挑战,需要新的治疗策略.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学 是一个学科.
背景情况:
- 肥胖是一种复杂的多因素疾病,具有重大的全球健康影响.
- 目前的肥胖药物疗法具有有限的疗效和安全性.
研究的目的:
- 审查内分泌系统 (ECS) 在肥胖病变发生中的作用.
- 评估针对ECS用于肥胖管理的治疗潜力.
主要方法:
- 对临床前和临床数据的综合文献综述.
- 评估内分类素联体,大麻素受体 (CB1,CB2) 和遗传变异.
- 针对ECS的药理干预措施的分析.
主要成果:
- 过度激活ECS与过度摄入食物,能量失衡和代谢障碍有关.
- 在动物模型中,ECS组件的药理学调制显示了抗肥胖作用.
- 临床翻译受到安全问题,特别是神经精神病学不良事件的阻碍.
结论:
- 欧洲脑神经系统是肥胖症的潜在治疗点.
- 对于安全有效的肥胖管理,需要新的策略,例如局部受限化合物和非药物干预措施.
相关概念视频
Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
666
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
666
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K


